Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Concordia acquires Covis Pharma commercial assets for $1.2bn
These products include 12 branded products, five authorized generic contracts and a product distributed by a third party in Australia pursuant to the terms of a distribution agreement.
These products include 12 branded products, five authorized generic contracts and a product distributed by a third party in Australia pursuant to the terms of a distribution agreement.
The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of BuTab in healthy subjects. Main objective of the trial is to assess if buprenorphine can be
The tablets are indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions. Epic will be
The collaboration is aimed at advancing a portfolio consisting of programs with new mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. As part
In the NIH-funded study, researchers found that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged
Teva has offered $82 for each Mylan share in this cash and stock deal, which is expected to transform the generic drugs industry. According to Teva, the proposal
Minocin for Injection is a tetracycline derivative approved in the US to treat infections due to susceptible strains of several important designated gram-positive and gram-negative pathogens, including infections
The expanded label now includes the addition of two thumb muscles: flexor pollicis longus and adductor pollicis; increasing the maximum dose from 360 to 400 units to teat
Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization and the product is scheduled to be launched in the second half of 2015.
The company’s second clinical compound, CCX872 is an orally administered inhibitor of the chemokine receptor known as CCR2. Around 54 patients with non-resectable pancreatic cancer will be included